Medtronic achieves three milestones for MiniMed 780G system in US
Beneficiaries of Medicare and Medicare Advantage can now obtain the MiniMed 780G system combined with the Instinct sensor.
03 February 2026
03 February 2026
Beneficiaries of Medicare and Medicare Advantage can now obtain the MiniMed 780G system combined with the Instinct sensor.
The data showed a favourable safety and tolerability profile consistent with earlier Zoryve clinical trials.
Aquestive plans a Type A FDA meeting and expects NDA resubmission in Q3 2026 after required studies.
The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.